Lung Cancer Clinical Trials in Salt Lake City

Showing 401-420 of 623 trials

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Breast CancerLung CancerHepatocellular Cancer+3 more

Novartis Pharmaceuticals120 participantsStarted Apr 2017

Nashville, Tennessee, United States • Salt Lake City, Utah, United States • Salzburg, Austria +9 more locations

COMPLETEDPhase 2< 1 mile

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

NCT03377556

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

ATM Gene MutationATR Gene MutationBARD1 Gene Mutation+18 more

SWOG Cancer Research Network51 participantsStarted Mar 2017

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +1154 more locations

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Lung Cancer Trials in Other Cities

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Safety Study of MGA271 in Refractory Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Other Conditions in Salt Lake City